Observe.AI Unveils AI Agents for Voice of Customer Intelligence
SAN FRANCISCO, June 05, 2025 (GLOBE NEWSWIRE) — Observe.AI, the leading AI platform for contact centers, today announced a major expansion of its GenAI Insights offering, introducing powerful new capabilities that unlock true voice of customer (VoC) insights and make them easily accessible across the enterprise through AI agents.
Since its founding eight years ago, Observe.AI has enabled enterprises to improve human and virtual agent performance and customer experience using conversation intelligence and insights. With the latest release of GenAI Insights, Observe.AI customers can now gain access to the most granular insights from 100% of customer conversations, including turn-by-turn sentiment shifts, root causes behind those changes, and top reasons customers reach out, all tied to key business outcomes. These insights are now available to every team across the organization via AI agents, enabling smarter, faster decisions at scale.
'Contact centers are home to the richest customer data in the enterprise, but that data has historically been locked behind siloed data systems, slow manual analysis, or complex tooling,' said Swapnil Jain, CEO and co-founder of Observe.AI. 'With this latest release, we're giving every team—not just analysts—on-demand access to deeper, smarter, evidence-based insights that drive business action.'
What's New with GenAI Insights: AskObserve – A natural language AI agent that's your conversational shortcut to insights. Teams can now simply ask questions like 'What's driving complaints about our billing process?' or 'Are customers mentioning competitor offers more often this quarter?' and receive real-time, structured answers that are backed by real data from conversations.
– A natural language AI agent that's your conversational shortcut to insights. Teams can now simply ask questions like 'What's driving complaints about our billing process?' or 'Are customers mentioning competitor offers more often this quarter?' and receive real-time, structured answers that are backed by real data from conversations. AI Studio – A no-code command center for teams to easily and quickly configure, test and fine-tune their AI-powered services to be incorporated into any workflows. Customize conversation outputs into free-text summaries, flag competitor or named mentions, identify key moments and categorize topics, tailored for any use case for any team.
– A no-code command center for teams to easily and quickly configure, test and fine-tune their AI-powered services to be incorporated into any workflows. Customize conversation outputs into free-text summaries, flag competitor or named mentions, identify key moments and categorize topics, tailored for any use case for any team. L1/L2/L3 Customer Contact Reasons – Go beyond surface-level topics to reveal the underlying 'why' behind customer interactions. GenAI Insights now breaks down conversations by first-level (L1), second-level (L2), and third-level (L3) contact reasons, offering a layered view that identifies behaviors and trends that impact first-contact resolution opportunities. For example, a CX team discovers that 'account cancellations' (L1) are often driven by 'long refund timelines' (L2) and 'lack of status updates' (L3), enabling precise fixes that reduce churn.
– Go beyond surface-level topics to reveal the underlying 'why' behind customer interactions. GenAI Insights now breaks down conversations by first-level (L1), second-level (L2), and third-level (L3) contact reasons, offering a layered view that identifies behaviors and trends that impact first-contact resolution opportunities. For example, a CX team discovers that 'account cancellations' (L1) are often driven by 'long refund timelines' (L2) and 'lack of status updates' (L3), enabling precise fixes that reduce churn. VoC Dashboards and Reporting – Ready-to-use VoC dashboards and customizable reports that track sentiment, contact reasons and how they connect. These dashboards surface operational metrics that matter most by linking them to real business outcomes and ROI. For example, an operations team sees that product-related calls with negative sentiment have the longest handle times, and works with the product team to preemptively address known issues.
'GenAI Insights is helping us unlock a new level of visibility into our customer conversations,' said Ryan Moore, VP, Customer Operations, DailyPay. 'We're no longer limited to manual reviews or partial samples—instead, we're surfacing patterns across millions of interactions to proactively spot issues via AskObserve, optimize workflows, and guide decision making. It's accelerating our ability to serve both customers and partners with greater precision and speed.'
Building on a Foundation of Insight Leadership
From day one, Observe.AI has enabled enterprises to tap into customer interaction insights to elevate quality assurance, agent coaching, and CX operations. The new release for GenAI Insights expansion takes this beyond the contact center—breaking down barriers to access and enhancing the granularity of insights for faster, smarter decision-making for all.
'With GenAI Insights, we're closing the gap between conversations and enterprise action,' added Jain. 'Whether you're in operations, marketing, compliance, or product, you're no longer waiting on weekly reports or manual reviews. The voice of the customer is now at your fingertips.'
Observe.AI's GenAI Insights are built on Observe.AI's enterprise-grade security architecture, including GDPR, HITRUST, HIPAA, SOC2, ISO27001, and other certifications, to deliver compliant and trusted conversations.
For more information about GenAI Insights, visit http://observe.ai/insights.
About Observe.AI
Observe.AI is transforming customer service with AI agents that speak, think, and act like your best human agents—helping enterprises automate routine customer calls and workflows, support agents in real time, and uncover powerful insights from every interaction.
With Observe.AI, businesses boost automation, deliver faster, more consistent 24/7 service and build stronger customer loyalty.
Trusted by brands like Accolade, Prudential, Concentrix, Cox Automotive, and Included Health, Observe.AI is redefining how businesses connect with customers—driving better experiences and lasting relationships at every touchpoint. For more information, please visit www.observe.ai.
Contact:Hannah Johnston
[email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the 'Grant Date'), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC's common stock on the Grant Date. Twenty-five percent (25%) of the shares subject to the stock options will vest on the one (1) year anniversary of the Grant Date, with one thirty-sixth (1/36th) of the remaining shares vesting each one-month period thereafter. One-third (1/3rd) of the restricted stock units will vest on each of the first three anniversaries of the Grant Date. The inducement grants are subject to the terms and conditions of the applicable stock option and restricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan. The inducement grants were approved by ORIC's Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4). About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to and follow us on X or LinkedIn. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the vesting of the inducement grants; target indications for ORIC's product candidates; the potential advantages of ORIC's product candidates; and plans underlying ORIC's clinical trials and development. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,' 'intends,' 'will,' 'goal,' 'potential' and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC's ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC's plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC's product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC's operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC's license and collaboration agreements; the potential market for our product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC's ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC's reliance on third parties, including contract manufacturers and contract research organizations; ORIC's ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in ORIC's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the 'SEC') on May 5, 2025, and ORIC's future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Contact:Dominic Piscitelli, Chief Financial info@ sesión para acceder a tu cartera de valores
Yahoo
37 minutes ago
- Yahoo
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), ('PolyPid' or the 'Company'), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. Conference Call Dial-In & Webcast Information: Date: Monday, June 9, 2025 Time: 8:30 AM Eastern Time Conference Call: Webcast: About PolyPid PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit and follow us on Twitter and LinkedIn. Contacts:PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@ Investors:Brian RitchieLifeSci Advisors212-915-2578britchie@
Yahoo
39 minutes ago
- Yahoo
AYR Announces Entry into Limited Waiver Agreement with Senior Noteholders
MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) ('AYR' or the 'Company'), a leading vertically integrated U.S. multi-state cannabis operator, announces that it has entered into a Limited Waiver Agreement (the 'Agreement') with the holders of a majority of its senior secured notes (the 'Majority Holders'). The Agreement provides a temporary waiver of certain events of default under the Company's senior note documents, including those arising from the Company's previously announced delay in filing its interim financial statements for the quarter ended March 31, 2025, and certain payment defaults under other outstanding debt obligations (including certain of the Company's unsecured and/or subordinated debt obligations) should the Company determine not to make such payments when due. The waiver is effective through June 19, 2025, unless terminated earlier upon the occurrence of certain specified events, including a termination event of default should the Company make any payments otherwise due under its unsecured and/or subordinated debt obligations. The Company is actively engaged in ongoing negotiations with its senior lenders and continues to assess strategic alternatives to address its capital structure and upcoming payment obligations. The entry into the Agreement provides the Company with additional time and flexibility to continue these discussions and pursue its strategic objectives. The Agreement temporarily restricts the Majority Holders from exercising their default-related rights and remedies with respect to the specified defaults during the waiver period, subject to the terms and conditions set forth in the Agreement. The Agreement does not constitute a permanent waiver of any defaults or a waiver of any other rights or remedies under the senior note documents. AYR remains committed to operating its business in the ordinary course and to delivering high-quality cannabis products to its patients and customers. The Company will continue to provide updates regarding the status of the Agreement and any material developments as they arise. Forward-Looking StatementsCertain statements contained in this news release may contain forward-looking information or may be forward-looking statements (collectively, 'forward-looking statements') within the meaning of applicable securities laws. Forward-looking statements are often, but not always, identified by the use of words such as 'target', 'expect', 'anticipate', 'believe', 'foresee', 'could', 'would', 'estimate', 'goal', 'outlook', 'intend', 'plan', 'seek', 'will', 'may', 'tracking', 'pacing' and 'should' and similar expressions or words suggesting future outcomes. This news release includes forward-looking statements pertaining to, among other things, the entry into the Agreement, the Company's ongoing negotiations with its senior lenders, the outcome of the strategic review process and the Company's ability to continue to operate in the ordinary course. Numerous risks and uncertainties could cause actual events and results to differ materially from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. AYR has no intention, and undertakes no obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. About AYR Wellness Wellness is a vertically integrated, U.S. multi-state cannabis business. The Company operates simultaneously as a retailer with 90+ licensed dispensaries and a house of cannabis CPG brands. AYR is committed to delivering high-quality cannabis products to its patients and customers while acting as a Force for Good for its team members and the communities that the Company serves. For more information, please visit Company/Media Contact:Robert VaniskoSVP, Public AffairsT: (786) 885-0397Email: comms@ Investor Relations Contact:Sean Mansouri, CFAElevate IRT: (786) 885-0397
